A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

NCT03575351 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Standard of Care
GENETIC: JCAR017

Sponsor

Celgene